Should I Buy Boston Scientific (BSX)? Finance YouTuber Analysis

The YouTuber identifies Boston Scientific as a pure Tier 1 robotics company, building physical systems for medical applications. Their Ferropulse platform uses robotic ablation for cardiac arrhythmias, showcasing full-stack integration of hardware, software, and navigation. Analysts project 28% upside as hospitals adopt next-gen robotic systems, though the YouTuber notes this is infrastructure and slower-moving.

“Analysts see roughly 28% upside ahead for BSX. As hospitals accelerate adoption of nextgen robotic systems like Ferropulse, the value in tier 1 is steady.”

The analyst suggests Boston Scientific, noting it did not experience a GLP-1 related sell-off and has no diabetes exposure. While cardiovascular devices make up a significant portion of its revenue, the company is still posting solid growth. He acknowledges the higher valuation at 27 times forward earnings but implies it's justified by the growth and lack of GLP-1 impact.

“Boston Scientific ticker bsx never really saw a glp1 related sell off in and the shares are now up 19% for the year.”